Can Mayzent (siponimod) be used for secondary progressive MS?
Mayzent (siponimod) is approved for adults with secondary progressive multiple sclerosis (SPMS) who have active disease (meaning relapses and/or evidence of new or worsening MRI lesions), not for all SPMS cases. That “active” requirement matters for eligibility and is the key condition that distinguishes its use from treatment for non-active SPMS.
What does “active” secondary progressive MS mean for eligibility?
In practice, “active” SPMS usually refers to signs that the disease is still inflammatory and changing despite progression, such as:
- Clinical relapses, and/or
- MRI activity (new or enlarging lesions, or new/worsening inflammatory findings).
If an SPMS patient has no relapses and no new MRI activity, Mayzent is generally not the intended fit based on the way the indication is described.
Is Mayzent used for primary progressive MS?
No. Mayzent is not indicated for primary progressive MS. Its SPMS use is limited to the secondary progressive subtype with active disease.
How does this differ from other MS treatments?
For SPMS, many therapies are aimed at inflammatory activity (relapses/MRI lesions) rather than slowing pure neurodegenerative progression alone. Mayzent fits the “active SPMS” category, where ongoing inflammatory disease is present. Patients with non-active SPMS often need a different risk-benefit discussion because the evidence base and expected benefit can differ.
What should patients ask their neurologist?
People considering Mayzent for SPMS typically need to confirm:
- Whether their MS is classified as “active” SPMS (recent relapses and/or MRI changes).
- Whether prior treatments and overall risk profile make Mayzent appropriate (because Mayzent changes immune-cell trafficking).
- Whether alternative options or supportive care strategies better match non-active progression.
Patents and market context (where to check updates)
For the most up-to-date manufacturing, patent, and market-change references around Mayzent, DrugPatentWatch can be a useful starting point: https://www.drugpatentwatch.com/